Niclonex (niclosamide suspension) / Imuneks - LARVOL DELTA

The Biosafety Evaluation for Crustaceans: A Novel Molluscicide PBQ Using against Oncomelania hupensis, the Intermediate Host of Schistosoma japonica. (PubMed, Trop Med Infect Dis) - "PBQ (20% SC), 26% metaldehyde, and niclosamide suspension concentrate [MNSC (26% SC)] were used both in ditch and field experiments for the molluscicidal efficacy comparison...Furthermore, it showed lower toxicity to the crustacean species, better solubility, no floating dust, and convenience for carriage. PBQ (20% SC) was suitable for controlling snails in the water network schistosomiasis-endemic areas."

Journal • Infectious Disease

Effectiveness and cost analysis of two chemical molluscicides in hilly schistosomiasis-endemic regions (PubMed, Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi) - "80% NESWP shows a high molluscicidal efficacy and low cost in hilly schistosomiasis-endemic regions."

HEOR • Journal • Infectious Disease

NICLONEX: A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19 (clinicaltrials.gov) - P3; N=200; Recruiting; Sponsor: Imuneks Farma ilac San. Tic. A.S.

Clinical • New P3 trial • Infectious Disease • Novel Coronavirus Disease